Publications by authors named "Colin F Spraggs"

Claim this Profile
N
New Approaches to Investigate Drug-Induced Hypersensitivity.
Monday O Ogese, Shaheda Ahmed, Ana Alferivic, Catherine J Betts, Anne Dickinson, Colin F Spraggs

Chem Res Toxicol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No Evidence for Drug-Specific Activation of Circulating T Cells from Patients with HLA-DRB1*07:01-Restricted Lapatinib-Induced Liver Injury.
Lee Faulkner, Xiaoli Meng, Dean J Naisbitt, Colin F Spraggs, B Kevin Park

Chem Res Toxicol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rash in lapatinib-treated patients is not associated with human leukocyte antigen polymorphisms.
Laura R Parham, Linda P Briley, Karen S King, Julie Byrne, Erica Rappold, Colin F Spraggs

Pharmacogenomics· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer.
Chun-Fang Xu, Toby Johnson, Xiaojing Wang, Chris Carpenter, Alan P Graves, Colin F Spraggs

Clin Cancer Res· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective validation of HLA-DRB1*07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury.
Daniel J Schaid, Colin F Spraggs, Shannon K McDonnell, Laura R Parham, Charles J Cox

J Clin Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A proposed modification to Hy's law and Edish criteria in oncology clinical trials using aggregated historical data.
Daniel Parks, Xiwu Lin, Jeffery L Painter, Jie Cheng, Christine M Hunt, Colin F Spraggs

Pharmacoepidemiol Drug Saf· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic characterization to improve interpretation and clinical management of hepatotoxicity caused by tyrosine kinase inhibitors.
Colin F Spraggs, Chun-Fang Xu, Christine M Hunt

Pharmacogenomics· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial.
A Karim Kader, Jielin Sun, Brian H Reck, Paul J Newcombe, Seong-Tae Kim, Colin F Spraggs

Eur Urol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of Bayesian and frequentist approaches to incorporating external information for the prediction of prostate cancer risk.
Paul J Newcombe, Brian H Reck, Jielin Sun, Greg T Platek, Claudio Verzilli, Colin F Spraggs

Genet Epidemiol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of the hemochromatosis gene with pazopanib-induced transaminase elevation in renal cell carcinoma.
Chun-Fang Xu, Brian H Reck, Vicki L Goodman, Zhengyu Xue, Lingkang Huang, Colin F Spraggs

J Hepatol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.
Chun-Fang Xu, Nan X Bing, Howard A Ball, Dilip Rajagopalan, Cora N Sternberg, Colin F Spraggs

J Clin Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer.
Colin F Spraggs, Laura R Budde, Linda P Briley, Nan Bing, Charles J Cox

J Clin Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects.
Colin F Spraggs, Sreekumar G Pillai, David Dow, Christal Douglas, Linda McCarthy

Pharmacogenet Genomics· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis